RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shield Therapeutics Stock

Shield Therapeutics Revenue 2024

Shield Therapeutics Revenue

29.22 M GBP

Ticker

STX.L

ISIN

GB00BYV81293

WKN

A2AE98

In 2024, Shield Therapeutics's sales reached 29.22 M GBP, a 123.28% difference from the 13.09 M GBP sales recorded in the previous year.

The Shield Therapeutics Revenue history

YEARREVENUE (undefined GBP)GROSS MARGIN (%)
2027e72.535,55
2026e53.467,53
2025e58.766,85
2024e29.2213,78
202313.0930,78
20225.544,70
20211.5235,48
202010.3986,96
20190.7232,55
201811.8897,38
20170.6475,67
20160.367,11
2015--
2014--
2013--
2012--

Shield Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Shield Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shield Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shield Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Shield Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Shield Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Shield Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shield Therapeutics’s growth potential.

Shield Therapeutics Revenue, EBIT and net profit per share

DateShield Therapeutics RevenueShield Therapeutics EBITShield Therapeutics Net Income
2027e72.53 M GBP4.53 M GBP2.5 M GBP
2026e53.46 M GBP-3.48 M GBP-5.18 M GBP
2025e58.76 M GBP-4.82 M GBP-7.84 M GBP
2024e29.22 M GBP-15.18 M GBP-15.9 M GBP
202313.09 M GBP-31.33 M GBP-33.29 M GBP
20225.5 M GBP-31.65 M GBP-49.79 M GBP
20211.52 M GBP-20.29 M GBP-19.68 M GBP
202010.39 M GBP-2.15 M GBP-2.63 M GBP
2019719,000 GBP-9.04 M GBP-8.8 M GBP
201811.88 M GBP-5.16 M GBP-1.79 M GBP
2017637,000 GBP-20.95 M GBP-19.59 M GBP
2016304,000 GBP-12.29 M GBP-15.02 M GBP
20150 GBP-6.43 M GBP-23.63 M GBP
20140 GBP-3.39 M GBP-12.91 M GBP
20130 GBP-3.84 M GBP-4.19 M GBP
20120 GBP-3.61 M GBP-3.15 M GBP

Shield Therapeutics stock margins

The Shield Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shield Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shield Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Shield Therapeutics's sales revenue. A higher gross margin percentage indicates that the Shield Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Shield Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Shield Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shield Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shield Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shield Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Shield Therapeutics Margin History

Shield Therapeutics Gross marginShield Therapeutics Profit marginShield Therapeutics EBIT marginShield Therapeutics Profit margin
2027e30.78 %6.25 %3.44 %
2026e30.78 %-6.5 %-9.69 %
2025e30.78 %-8.2 %-13.34 %
2024e30.78 %-51.96 %-54.44 %
202330.78 %-239.44 %-254.44 %
202244.7 %-575.49 %-905.42 %
202135.48 %-1,336.01 %-1,295.46 %
202086.96 %-20.74 %-25.32 %
201932.55 %-1,256.61 %-1,223.92 %
201897.38 %-43.42 %-15.08 %
201775.67 %-3,289.01 %-3,075.04 %
201667.11 %-4,043.75 %-4,939.47 %
201530.78 %0 %0 %
201430.78 %0 %0 %
201330.78 %0 %0 %
201230.78 %0 %0 %

Shield Therapeutics Aktienanalyse

What does Shield Therapeutics do?

The company Shield Therapeutics PLC is a renowned British pharmaceutical conglomerate, founded in 2008. Based in Gateshead, England, Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. The company also has a strong presence in Europe and Asia. Shield Therapeutics' business model is to provide high-quality and innovative medical solutions to improve people's health and well-being. The company continuously researches new products to better cater to the needs of patients and doctors. The focus of Shield Therapeutics is on combating iron deficiency anemia, a severe blood disorder caused by a lack of iron in the body. Iron deficiency can be attributed to various factors, such as inadequate food intake, blood loss, or iron deficiency accumulation due to diseases. This anemia can lead to a range of symptoms, including fatigue, weak muscles, and dizziness. Long-term consequences can include life-threatening complications such as heart failure and strokes. Shield Therapeutics offers various products that can be used to treat iron deficiency anemia, such as Feraccru (in injection form) and Accrufer / Accrufer Tablets (in tablet form). Feraccru is an orally absorbed iron preparation indicated for the treatment of anemia in adults with iron deficiency anemia. Accrufer / Accrufer Tablets is an iron salt complex that is rapidly absorbed and shows high efficacy. The company also has its own research and development department, which focuses on researching innovative therapies and treatment methods. Shield Therapeutics actively participates in clinical research and the development of new therapeutic options aimed at improving the quality of life for people with iron deficiency anemia. More recently, Shield Therapeutics has also ventured into other disease areas. The company has developed clinical studies in collaboration with a top 10 pharmaceutical company to modify atherosclerosis through iron chelators. This is a groundbreaking research field that aims to develop advanced therapies for the treatment of infertility and chronic obstructive pulmonary disease (COPD). Overall, Shield Therapeutics has experienced strong growth in recent years and has solidified its position as a leading provider of pharmaceutical products for the treatment of iron deficiency anemia. The company has developed a wide range of products and can rely on a strong research and development department that constantly faces new challenges and offers innovative solutions for a variety of health issues. If Shield Therapeutics continues to be successful, it will undoubtedly continue to play a significant role in the industry. Answer: The company Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. Shield Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Shield Therapeutics's Sales Figures

The sales figures of Shield Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Shield Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Shield Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Shield Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Shield Therapeutics stock

How much revenue did Shield Therapeutics generate this year?

Shield Therapeutics has achieved a revenue of 29.22 M GBP this year.

How much was the turnover of the company Shield Therapeutics compared to the previous year?

The revenue of Shield Therapeutics has increased by 123.28% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Shield Therapeutics?

The revenue of Shield Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Shield Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Shield Therapeutics so important for investors?

The revenue of Shield Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Shield Therapeutics pay?

Over the past 12 months, Shield Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shield Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of Shield Therapeutics?

The current dividend yield of Shield Therapeutics is .

When does Shield Therapeutics pay dividends?

Shield Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shield Therapeutics?

Shield Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Shield Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shield Therapeutics located?

Shield Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shield Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shield Therapeutics from 9/9/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Shield Therapeutics pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Shield Therapeutics in the year 2023?

In the year 2023, Shield Therapeutics distributed 0 GBP as dividends.

In which currency does Shield Therapeutics pay out the dividend?

The dividends of Shield Therapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shield Therapeutics

Our stock analysis for Shield Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shield Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.